Nuvation Bio Inc. Reports Third Quarter 2026 Financial Results

Nuvation Bio reported third-quarter 2026 revenue of $45.0 million for the period ended September 30, exceeding the FactSet analyst consensus estimate of $34.4 million. The November 4 earnings release also included a business update on the company’s commercial-stage operations and financial position. The article did not provide profit figures or report a stock-price reaction.